» Articles » PMID: 31732298

MiR24-2 Promotes Malignant Progression of Human Liver Cancer Stem Cells by Enhancing Tyrosine Kinase Src Epigenetically

Overview
Journal Mol Ther
Publisher Cell Press
Date 2019 Nov 17
PMID 31732298
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNA24-2 (miR24-2) is associated with human tumorigenesis; however, its molecular mechanisms are poorly understood. Herein, our findings demonstrate that miR24-2 promotes the proliferation ability in vitro and the tumorigenic ability in vivo in human liver cancer stem cells (hLCSCs). Mechanically, the miR24-2 targets for 3' UTR (2,627-2,648) of protein arginine methyltransferase 7 (PRMT7) inhibit the translational ability of prmt7 gene. Moreover, miR24-2 inhibits the di-/tri-methylation of histone H4 arginine 3 by reducing PRMT7 and then promotes the expression of Nanog via long noncoding RNA HULC. Notably, miR24-2 inhibits histone deacetylase HDAC3 through miR675, which promotes the acetylation of histone H4 at lysine 16. Subsequently, miR24-2 enhances the interaction between LC3 and ATG4 dependent on PI3K and triggers cellular autophagy. Strikingly, miR24-2 inhibits the degradation of pyruvate kinase M1 via autophagosome-P62 in hLCSCs. Furthermore, miR24-2 enhances the activity of Src by promoting the binding of PKM1 to the Src promoter regions in hLCSCs. In particular, our results also indicate that src gene determines the oncogenic functions of miR24-2. These results provided a valuable theoretical basis for the discovery of liver cancer therapeutic targets and diagnosis markers based on miR24-2.

Citing Articles

Research Progress of Liver Cancer Recurrence Based on Energy Metabolism of Liver Cancer Stem Cells.

Wu M, Wang H, Wu X, Zeng H, Miao M, Song Y J Hepatocell Carcinoma. 2025; 12:467-480.

PMID: 40061164 PMC: 11887506. DOI: 10.2147/JHC.S500638.


Epigenetic modifications involving ncRNAs in digestive system cancers: focus on histone modification.

Yin X, Li J, Zhao J, Zheng W, Zhang A, Ma J Clin Epigenetics. 2024; 16(1):162.

PMID: 39563475 PMC: 11577885. DOI: 10.1186/s13148-024-01773-0.


Autophagy and cancer therapy.

Pimentel J, Zhou J, Wu G Cancer Lett. 2024; 605:217285.

PMID: 39395780 PMC: 11665950. DOI: 10.1016/j.canlet.2024.217285.


Writers, readers, and erasers RNA modifications and drug resistance in cancer.

Chen D, Gu X, Nurzat Y, Xu L, Li X, Wu L Mol Cancer. 2024; 23(1):178.

PMID: 39215288 PMC: 11363509. DOI: 10.1186/s12943-024-02089-6.


Cancer metastases: Tailoring the targets.

Pote M, Singh D, M A A, Suchita J, Gacche R Heliyon. 2024; 10(15):e35369.

PMID: 39170575 PMC: 11336595. DOI: 10.1016/j.heliyon.2024.e35369.


References
1.
Manvati S, Mangalhara K, Kalaiarasan P, Srivastava N, Bamezai R . miR-24-2 regulates genes in survival pathway and demonstrates potential in reducing cellular viability in combination with docetaxel. Gene. 2015; 567(2):217-24. DOI: 10.1016/j.gene.2015.05.003. View

2.
Bernt K, Zhu N, Sinha A, Vempati S, Faber J, Krivtsov A . MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011; 20(1):66-78. PMC: 3329803. DOI: 10.1016/j.ccr.2011.06.010. View

3.
Radoshevich L, Murrow L, Chen N, Fernandez E, Roy S, Fung C . ATG12 conjugation to ATG3 regulates mitochondrial homeostasis and cell death. Cell. 2010; 142(4):590-600. PMC: 2925044. DOI: 10.1016/j.cell.2010.07.018. View

4.
Brejc K, Bian Q, Uzawa S, Wheeler B, Anderson E, King D . Dynamic Control of X Chromosome Conformation and Repression by a Histone H4K20 Demethylase. Cell. 2017; 171(1):85-102.e23. PMC: 5678999. DOI: 10.1016/j.cell.2017.07.041. View

5.
Ishizawar R, Parsons S . c-Src and cooperating partners in human cancer. Cancer Cell. 2004; 6(3):209-14. DOI: 10.1016/j.ccr.2004.09.001. View